Abstract: The present invention relates to an immune function inspection method, comprising obtaining peripheral blood from a human test subject; applying an immunostimulant; inspecting changes in intracellular calcium ion concentration in peripheral blood mononuclear cells (PBMC) or CD8T cells; determining a decrease in systemic immune function when the intracellular calcium ion concentration in PBMC or CD8T cells transiently increases after the application of the immunostimulant and then returns to the state before the stimulation; and determining normality of systemic immune function when the intracellular calcium ion concentration in PBMC or CD8T cells is in an upward trend after the application of the immunostimulant.

Abstract: The invention provides a method for enhancing immune cell function by activating various immune cells ex vivo and provides immune cells with enhanced function. The invention further provides an immune-related cell multifunctionality evaluation method. A biguanide antidiabetic drug selected from metformin, phenformin, and buformin is capable of enhancing immune cell multifunctionality by increasing CD8+T cells having a high ability to produce IL-2, INF?, and IFN?. The immune-related cell multifunctionality may be evaluated by comparing immune cells treated with a biguanide antidiabetic drug selected from metformin, phenformin, and buformin, with control immune cells untreated with the biguanide antidiabetic drug.

Abstract: The present invention provides a method for enhancing immune cell function by activating various immune cells ex vivo and provides immune cells with enhanced function. The invention further provides an immune-related cell multifunctionality evaluation method. A biguanide antidiabetic drug selected from metformin, phenformin, and buformin is capable of enhancing immune cell multifunctionality by increasing CD8+T cells having a high ability to produce IL-2, INF?, and IFN?. The immune-related cell multifunctionality may be evaluated by comparing immune cells treated with a biguanide antidiabetic drug selected from metformin, phenformin, and buformin, with control immune cells untreated with the biguanide antidiabetic drug.

Abstract: [Summary] The present invention relates an anti-HSP90 antibody and use thereof, more specifically to an anti-HSP90 antibody capable of recognizing cell surface HSP90, a vaccine that utilizes the antibody, a drug that utilizes the antibody, an adjuvant comprising the antibody, a method of detecting a cell expressing HSP90 on the cell surface using the antibody, and the like.

Abstract: The present invention provides a cell-death-inducing vector containing a gene encoding PA28. The present invention provides a cell-death-inducing agent characterized by comprising the cell-death-inducing vector. The present invention further provides an antitumor pharmaceutical composition characterized by comprising the cell-death-inducing vector.